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The Health Innovation Gap Ranking Project focuses on creating a framework to systematically 
identify priority areas among diseases and conditions that would benefit from research and 
development (R&D) investment.  
This report aims to identify disease categories with the highest economic and social costs and a 
low level of R&D investment.  First, we combine data sets on diseases’ medical expenses, patient 
counts, death rates, and research funding. We then use text mining and machine learning 
methods to identify gaps between diseases’ social and economic costs and research investments 
in therapeutic areas.  
We find that only 25 percent of disease categories causing high economic and social costs 
received more than 1 percent of National Institutes of Health (NIH) funding over 12 years. In 
addition, rare diseases imposing high medical costs per patient collected 0.3 percent of research 
investments on average.  
A disease’s cost and impact on society are challenging to assess. Our results highlight that the 
different measures may lead to different conclusions if considered separately: A disease can 
have a very high cost per patient but a low death rate. They also show that merging information 
across data sets becomes more complicated when the sources do not focus on diseases 
specifically.   
Our analysis reveals that a formalized procedure to define the correspondence between data 
sets is needed to successfully develop a metric that allows a systematic assessment of diseases’ 
cost, impact on society, and investment level. Furthermore, the simplification of the large 
dimensional decision space will only be useful to the questions at hand if there is a clear order 
of priorities. In our case, the first was the costs and then funding. These priorities dictate how to 





As part of the partnership between FasterCures, a Center of the Milken Institute, and the US 
Department of Health and Human Services (HHS) Accelerate Clinical Innovation (ACI) Initiative, 
the Milken Institute research department was asked to provide methodological and technical 
input to the Health Innovation Gap Ranking Project and to contribute to the Biomedical 
Ecosystem Metrics Initiative. This initiative is part of the 2018-2022 HHS strategic plan that 
focuses on five goals: “(i) Reforming, Strengthening, and Modernizing the Nation’s Healthcare 
System, (ii) Protecting the Health of Americans Where They Live, Work, Learn, and Play, (iii) 
Strengthening the Economic and Social Well-Being of Americans Across the Life-Span, (iv) 
Fostering Sound, Sustained Advances in the Sciences, and (v) Promoting Effective Management 
and Stewardship.”1 
The Health Innovation Gap Ranking Project focuses on creating a framework to systematically 
identify priority areas among diseases and conditions that would benefit from research and 
development (R&D) investment. The prioritization of the diseases and conditions would reflect 
their impact on public health, their cost to the health-care system, and the absence of recent 
related biomedical innovation.  
 
This paper contributes to this effort by identifying disease categories with the highest economic 
and social costs and a low level of R&D investment. We approximate the economic and social 
costs by a disease’s medical expense level, its number of patients, and mortality rate. The level of 
NIH funding received is a proxy for the R&D investment. Indeed, Packalen and Bhattacharya 
(2020) show the importance of NIH funding for innovative research, which often leads to 
biomedicine advancement. NIH funding was $2 trillion over the past 12 years.   
 
Specifically, we suggest a methodology on (1) how to merge information from different sources 
to assess the economic and social cost per disease so that the match between data sets is close 
                                                          
1. See hhs.gov for more details. 
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to 100 percent and (2) how to identify clusters of diseases with high medical cost, number of 
patients, or high mortality rate.  
 
Our results illustrate the benefit of new methods such as text mining and machine learning in 
merging and sorting information. They also emphasize the necessity of a standardized 
equivalence procedure between databases’ disease and condition categories to reconcile 
information sources. The reconciliation of information sources is an essential step when 
designing the framework for any systematic assessment of the cost, funding, and other 
dimensions of the disease or condition level. Finally, the order in which the data sets are merged 
impacts the final data set’s information, highlighting the importance of prioritizing information 
when merging data. 
 
The paper first describes the different data sets and how to merge them. Then it explains the 
methodology before presenting the results and some concluding remarks. 
 
Data 
We need to combine the following data sets to obtain information about health-care spending, 
the number of patients, mortality rates, and research funding per disease.  
Health Care Spending: The Blended Account database, from the Bureau of Economic Analysis 
(BEA) of the US Department of Commerce, estimates the annual health-care expenses and the 
number of patients per disease type.2 The Blended Account database relies on three data 
sources: the Medical Expenditure Panel Survey (MEPS), a patient-level health-care claims 
database from Truven Health Analytics, and a 5 percent random sample of Medicare 
beneficiaries. The MEPS collects data on approximately 15,000 families and 35,000 individuals 
each year. Because of its relatively small sample size compared to the total US population, the 
MEPS produces volatile estimates across years. The Blended Account database overcomes this 
issue by including the other two broad claims databases: the Truven Health MarketScan 
                                                          
2. Dunn, Rittmueller, and Whitmire (2015). 
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Commercial Database, which contains patient-level health-care claims information from 
employers and health plans, and Medicare data, which consist of claims from a 5 percent 
random sample of beneficiaries in fee-for-service Medicare. Both the Truven Health and 
Medicare 5 percent claims data capture information on millions of enrollees and billions of 
claims. We use estimates of annual spending per patient, the annual patient counts, and yearly 
total medical expenditures from the data. The Blended Account database has a total of 262 
disease categories for the period from 2000 to 2016. 
Mortality Rates: The Centers for Disease Control and Prevention’s (CDC’s) Wide-ranging Online 
Data for Epidemiologic Research (WONDER) project reports the total number of deaths, based 
on the death certificates of US residents. The underlying cause of death is selected from the 
conditions entered by the physician on the death certificate.3 The WONDER data contain 5,016 
causes of deaths for the period from 2000 to 2018.  
Funding for Innovative Research: In 2008, NIH implemented a new process to improve 
consistency and transparency in the reporting of its funded research. The Research, Condition, 
and Disease Categorization (RCDC) system uses text data mining (categorizing and clustering 
using words and multiword phrases) in conjunction with NIH-wide definitions to assign the 
funded research topics to categories. The NIH data report 296 RCDC research categories for the 
period from 2008 to 2019. 
Methodology 
Each data set has its definition and number of disease categories. While the cost-related data 
(i.e., health-care spending, number of patients, and mortality rates) are disease-related, the NIH 
funding categories are related to research area. Hence, merging these data sets requires several 
steps. 
                                                          
3. The World Health Organization defines “underlying cause of death” as “the disease or injury which 
initiated the train of events leading directly to death, or the circumstances of the accident or violence 
which produced the fatal injury.” Specifically, the underlying cause of death is selected from the 
conditions entered by the physician on the cause of death section of the death certificate. When more 
than one cause or condition is entered by the physician, the underlying cause is determined by the 
sequence of conditions on the certificate, provisions of the International Classification of Diseases, and 
associated selection rules and modifications. 
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We first identify a set of common disease categories based on the cost-related data. We then 
use the combined information to sort the disease categories based on their medical expenses, 
number of patients, and mortality rates. Finally, we match these classes of disease categories 
with the NIH funding. Below we provide more technical details on this three-step approach. 
Step 1: Common Disease Categories 
The health-care spending and number of patients data from BEA use 262 Clinical Classification 
Software (CCS) disease categories. In contrast, the CDC’s mortality data follow the International 
Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). The mortality data 
include 6,088 unique causes of deaths denoted as ICD-10-CM, from 2000 to 2018. We excluded 
deaths related to unavoidable accidents, terrorism, and war, which results in 5,016 causes of 
death considered for this study.4 Merging both data sets requires the creation of a common set 
of exclusive disease categories.  
We choose the CCS disease categories as a benchmark for the common disease categories 
because of their simplicity and widespread use in the literature. The metafile in the Clinical 
Classifications Software Refined (CCSR), an off-the-shelf software product, allows us to match 
the CCS and ICD-10-CM. We find the CCS codes for 4,601 of 5,016 ICD-10-CM codes. This direct 
approach matches 92 percent of the data.5  
Then, we use a text mining method to match the remaining 415 ICD-10-CM codes to CCS 
disease categories. More specifically, we collect text files describing the disease related to each 
ICD-10-CM code and each cause of death. We extract key medical terminologies from these 
descriptions and employ the Edit Distance algorithm to find the most similar pairs between the 
ICD-10-CM descriptions and causes of death descriptions. The text-analytic method examines 
the patterns of letters in a word and calculates the minimum number of operations required to 
                                                          
4. We dropped U, V, W, X, and Y codes in ICD-10-CM. 
5. The CCSR is one in a family of databases and software tools developed as part of the Healthcare Cost 
and Utilization Project (https://www.hcup-us.ahrq.gov/overview.jsp), a federal-state-industry partnership 
sponsored by the Agency for Healthcare Research and Quality. The metafile contains 72,436 ICD-10-CM 
codes with descriptions and corresponding CCS codes with descriptions.  
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transform one word into another.6 For example, “Delusional disorder” needs one operation (the 
insertion of a letter) to become “Delusional disorders.” We select the description pairs with the 
lowest edit distance—that is, the most similar sentences. Our manual crosschecks of the results 
find that simple typographical errors in a word, discrepancies in the use of singular or plural 
forms of medical terminology, or a different order of words in a sentence cause most 
mismatches created by the metafile in the CCSR software tool. Overall, we can match 99 percent 
of the data. Only 62 causes of death remain unmatched and are removed from the analysis.7   
Step 2: Clustering of the Disease Categories 
As noted above, our primary goal is to identify the disease categories with relatively high health-
care costs or mortality rates and low innovative research funding.  
Figure 1 confirms that only a few CCS disease categories have substantially higher death rates 
and medical expenses than the others. It also shows that high mortality diseases do not 
correspond to diseases with high medical expenses. For example, only one disease category is 
among the top seven annual averages for both mortality rates and medical costs: coronary 
atherosclerosis and other heart diseases. Similarly, there is no benchmark defining relatively and 
statistically higher death rates and medical costs, except for a few outliers, making conventional 
statistics inappropriate to identify our groups of interest. Finally, we consider estimates of annual 
spending per patient to identify costly disease categories and the yearly patient counts as a 
proxy for the prevalence of diseases, in addition to two variables in Figure 1. Using multiple 
variables further complicates a conventional statistical methods approach.  
  
                                                          
6. In computational linguistics and computer science, edit distance is a way to quantify how similar 
two strings (e.g., words) are to one another by counting the minimum number of operations required to 
transform one string into the other. Edit distances find applications in natural language processing, where 
automatic spelling correction can determine candidate corrections for a misspelled word by selecting 
words from a dictionary that have a low distance to the word in question. In bioinformatics, it can be used 
to quantify the similarity of DNA sequences, which can be viewed as strings of the letters A, C, G, and T 
(Wikipedia, n.d.). 
7. Combining the mortality data with health-care data from BEA excludes 30 disease categories in the BEA 
data, which are related to pure accidents or not involved with death. 
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Figure 1: CCS Disease Categories with High Mortality Rates and High Health-Care Costs 
 
Note: The left panel shows the total number of deaths per 100,000 individuals caused by specific CCS disease categories 
from 2000 to 2018. All values are yearly aggregate values. The right panel indicates annual health-care expenses from 
2000 to 2016 to treat different diseases in CCS categories. The top seven CCS disease categories in terms of average 
values are highlighted in different colors and described in the box. 
Source: Authors’ calculation using CDC’s WONDER and Blended Account database from BEA (2020) 
 
In contrast, machine learning methods automatically partition data into mutually exclusive 
clusters based on the data’s intrinsic structure. Our analysis focuses on above-average behavior, 
high health-care cost, or mortality rate. As a result, we prefer k-means clustering to other 
popular algorithms, such as Density-Based Spatial Clustering of Applications with Noise 
(DBSCAN) and Gaussian Mixture Models, which would combine the outliers in a separate cluster. 
We also let the data dictate the optimal number of clusters, k.8 More specifically, we calculate 
                                                          
8. k-means algorithm tries to partition the data set into k pre-determined distinct subgroups. It assigns 
data points to a cluster such that the sum of the squared distance between the data points and the 
cluster’s centroid is at the minimum. The less variation we have within clusters, the more similar the data 
points are within the same cluster.  
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the silhouette value, which measures how close each point in one cluster is to points in the 
neighboring clusters (Rousseeuw, 1987). The silhouette ranges from -1 to +1, where a high value 
indicates that the object is well matched to its cluster and poorly matched to neighboring 
clusters. If most objects have a high value, then the clustering configuration is appropriate. If 
most objects have a low or negative value, then the clustering configuration may have too many 
or too few clusters. The best number of clusters, k, maximizes the average silhouette values for 
all observations.  
Before implementing the method, we normalize the mortality and medical expenses due to the 
different values’ scales. In line with any machine learning algorithms, the k-means method 
involves a numerical minimization problem. To avoid local minima, we repeat the clustering 
process starting from different randomly selected points for centroids of clusters. We then 
choose the solution with the lowest total sum of distances among all the replicates. 
Our results cluster the CCS disease categories into four classes. The summary statistics reported 
in Table 1 help describe them as follows: 
• Class 1 consists of the 183 CCS disease categories that have neither a high cost 
nor a high mortality rate. We disregard this class as not relevant to our question.  
• Class 2 consists of the 21 CCS disease categories with the most patients and the 
overall highest yearly medical expenses.  
• Class 3 consists of the 23 CCS disease categories with the highest yearly cost per 
patient. 
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Note: This table shows a yearly average of four variables within a class. Deaths per 100,000 individuals are based on the 
CDC data from 2000 to 2018. The annual patient counts and health-care expenses within a class are averaged from 
2000 to 2016. Standard deviations are in parentheses.  
 
Source: Authors’ calculation using CDC’s WONDER and Blended Account database from BEA (2020) 
 
 
Step 3: NIH Funding of the Clusters 2, 3, and 4  
We focus on the classes that capture either high medical costs (Classes 2 and 3) or high 
mortality rates (Class 4) and reconcile the CCS disease categories included in each class with NIH 
classification.    
The categories represented in the RCDC of the NIH funding data differ from the CCS disease 
categories. Many RCDC categories are research areas (such as genetics or neuroscience), specific 
populations (such as pediatrics or minority health), or rare diseases (such as Pick’s disease). 
Given RCDC’s focus on categorizing research areas rather than classifying specific causes of 
death and medical expenses, the category definitions and delineations used in the RCDC do not 
always match those of the CCS. We have to match the 296 different RCDC research categories 
with the 49 CCS disease categories remaining. We use the extracted key medical terminologies 
to link RCDC and CCS disease categories.9 Among the 49 CCS disease categories, we found 32 
                                                          
9. The differing characteristics of the two data sets mean that there are caveats to interpreting the 
matched data and that there are still judgment calls required in some cases to determine the best fits 
between the two sources. 
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CCS matched to the RCDC. The 32 CCS are matched to 92 different RCDCs, which comprise 25 
percent ($509 billion) of NIH funding from 2008 to 2019.  
We focus on 32 CCS disease categories for our final analysis, which identifies low-invested but 




Figures 2 to 6 plot the NIH funding level, death rates, the number of patients, medical expenses 
per patient, and total medical expenses for the CCS disease categories included in Classes 2, 3, 
and 4. Table 2 and Appendix 4 provide more details on the CCS disease categories by listing the 
NIH categories included in each one.  
Overall, our results highlight three key findings. First, we do not find any clear pattern between 
funding allocations and the diseases’ social and economic costs. Specifically, as Figure 2 
indicates, NIH funding allocated to the top five CCS disease categories in terms of the aggregate 
funding amount (17.8 percent) almost doubles the funding distributed to all other 27 CCS 
disease categories with high medical costs or mortality (9.7 percent). Similarly, 12 CCS disease 
categories in Figure 2 have received less than 1 percent of NIH funding during the past 12 years. 
Figures 3 to 6 also show that NIH funding is disproportionately allocated to specific CCS disease 
categories within a class and does not align with the order of the death rates, patient counts, or 
costs per patient.  
Second, Figure 5 shows that most CCS disease categories imposing high medical costs per 
patient have received little NIH funding. Specifically, all 14 CCS disease categories in Class 3 
collected 3.8 percent of NIH funding, but that percentage becomes 1.5 percent if we remove 
funding focused on HIV infection.  
Third, different measures of a disease’s cost and social impact lead to different conclusions: 
Some diseases cause many deaths, while others impose a significant monetary burden on 
society. For example, a CCS category, immunizations and screening for infectious disease, has 
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the largest number of patients (46 million) but has the smallest yearly cost per patient ($487). 
Another CCS category, cystic fibrosis, is the costliest disease ($19,802 for an average annual cost 
per patient) but rare (less than 50,000 cases nationally), while cancer of bronchus (lung) is one of 
the deadliest diseases but causes relatively lower medical expenses to society. Our data-centric 
approach considers all the different measures while simplifying the decision-making process in 




Figure 2: Proportion of NIH Funding toward CCS Diseases Categories 
Note: Proportions of NIH funding onto CCS disease categories are based on an aggregate amount of NIH funding from 
2008 to 2019. Some CCS category names are abbreviated for better readability. See footnote for the full version.10  
                                                          
10 This table shows the full CCS disease category descriptions of the ones abbreviated by authors for 
better readability in Figures 2 to 6. 
Abbreviated CCS Disease Categories Full CCS Disease Category Descriptions 
Brain cancer Cancer of brain and nervous system 
Lung cancer Cancer of bronchus; lung 
Liver cancer Cancer of liver and intrahepatic bile duct 
Rectal/Anal cancer Cancer of rectum and anus 
Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease and bronchiectasis 
Heart Disease Coronary atherosclerosis and other heart disease 
Cognitive disorders Delirium dementia and amnestic and other cognitive disorders 
Diabetes mellitus Diabetes mellitus without complication 
Hypertension Essential hypertension 
Screening for infectious disease Immunizations and screening for infectious disease 
Lymphoma Non-Hodgkin`s lymphoma 
Connective tissue diseases Other connective tissue disease 
Gastrointestinal disorders Other gastrointestinal disorders 
Lower respiratory disease Other lower respiratory disease 
Nervous system disorders Other nervous system disorders 




Source: Authors’ calculation using CDC’s WONDER, Blended Account database from BEA, and NIH’s estimates of funding 
for RCDC (2020) 
 
Figure 3: Deaths per CCS Disease Category 
 
Note: Each bar indicates the average number of annual deaths per 100,000. Diamonds show the proportion of NIH 
funding allocated to a CCS disease category. Some CCS category names are abbreviated for better readability.  See 
footnote 10 for the full version. 
Source: Authors’ calculation using CDC’s WONDER, Blended Account database from BEA, and NIH’s estimates of funding 
for RCDC (2020) 
                                                          
Other screening for conditions 
Other screening for suspected conditions (not mental disorders or 
infectious disease) 
Skin disorders Other skin disorders 
Upper respiratory disease Other upper respiratory disease 
Sepsis Septicemia (except in labor) 
Labor & fetal complications Short gestation; low birth weight; and fetal growth retardation 






Figure 4: Number of Patients per CCS Disease Category 
 
Note: Each bar indicates the average number of patients in a year. Diamonds show the proportion of NIH funding 
allocated to a CCS disease category. Some CCS category names are abbreviated for better readability. See footnote 10 
for the full version. 
 
Source: Authors’ calculation using CDC’s WONDER, Blended Account database from BEA, and NIH’s estimates of funding 








Figure 5: Medical Expenses per Patient per CCS Disease Category 
 
Note: Each bar indicates the average annual medical spending of patients having diseases associated with a CCS 
disease category. Diamonds show the proportion of NIH funding allocated to a CCS disease category. Some CCS 
category names are abbreviated for better readability. See footnote 10 for the full version. 
 
Source: Authors’ calculation using CDC’s WONDER, Blended Account database from the BEA, and NIH’s estimates of 




Figure 6: Total Medical Expenses per CCS Disease Category 
 
Note: Each bar indicates the yearly average total medical expenses spent on a CCS disease category. Diamonds show 
the proportion of NIH funding allocated to a CCS disease category. Some CCS category names are abbreviated for 
better readability. See footnote 10 for the full version. 
 
Source: Authors’ calculation using CDC’s WONDER, Blended Account database from the BEA, and NIH’s estimates of 






Table 2: CCS/NIH Disease Categories with the Most NIH Funding  
Disease Categories  Funding Allocation 
CCS NIH  NIH  CCS  
Immunizations and 







Infectious Diseases   2.9% 
5.7% 
Emerging Infectious Diseases   1.4% 
Immunization   1.1% 
Vector-Borne Diseases   0.3% 
Malaria Vaccine   <0.1% 
Tuberculosis Vaccine   <0.1% 
Other nervous system 
disorders 
Brain Disorders Neurodegenerative, 
Neuroblastoma, Myasthenia Gravis, 
Fibromyalgia 
  2.7% 
4.3% 
  Neurodegenerative   1.2% 
  Epilepsy   <0.1% 
  Peripheral Neuropathy   <0.1% 
  Spinal Cord Injury   <0.1% 
  ALS   <0.1% 
  
Transmissible Spongiform Encephalopathy 
(TSE)   
  <0.1% 
  Neuroblastoma   <0.1% 
  Neurofibromatosis   <0.1% 
  Rett Syndrome   <0.1% 
  Spina Bifida   <0.1% 
  Charcot-Marie-Tooth Disease Injury   <0.1% 
  Fibromyalgia   <0.1% 
  Ataxia Telangiectasia   <0.1% 
  Myasthenia Gravis   <0.1% 
  Tourette Syndrome   <0.1% 
  Batten Disease   <0.1% 
Disease Categories  Funding Allocation 
CCS NIH  NIH CCS  
  
Delirium, dementia, 








Neurodegenerative   1.2% 
3.3% 
Alzheimer’s Disease   0.5% 
Dementia   0.4% 
Acquired Cognitive Impairment   0.4% 
Alzheimer’s Disease including Alzheimer’s 
Disease-Related Dementias (AD/ADRD) 
  0.4% 
Parkinson’s Disease   <0.1% 
Alzheimer’s Disease-Related Dementias 
(ADRD) 
  <0.1% 
Vascular Cognitive Impairment/Dementia   <0.1% 








Frontotemporal Dementia (FTD)   <0.1% 
Aphasia 
  <0.1% 
 Lewy Body Dementia  <0.1%  
 Pick’s Disease  <0.1%  
 
Disease Categories  Funding Allocation 
CCS NIH  NIH  CCS  
HIV infection HIV/AIDS   1.8% 
2.3%   Vaccine-related (AIDS)   0.3% 
  Pediatric AIDS   0.1% 
Mood disorders Mental Health   1.5% 
2.1% 
  Depression   0.3% 
  Mental Illness   0.2% 
  Serious Mental Illness   0.1% 
  Major Depressive Disorder   <0.1% 
  Bipolar Disorder   <0.1% 
Coronary atherosclerosis and 
other heart disease 
Heart Disease   0.8% 
1.6% 
  Atherosclerosis   0.3% 
  Heart Disease—Coronary Heart Disease   0.3% 
  Stroke   0.2% 
  Congenital Heart Disease   <0.1% 
  Pediatric Cardiomyopathy   <0.1% 
Other gastrointestinal 
disorders 
Digestive Disease   1% 
1.2% 
  Inflammatory Bowel Disease   <0.1% 
  Crohn’s Disease   <0.1% 
  Digestive Diseases (Peptic Ulcer)   <0.1% 
  Digestive Diseases (Gallbladder)   <0.1% 
Other screening for 
suspected conditions (not 
mental disorders or 
infectious disease) 
Vaccine-related   1.1% 1.1% 
Diabetes mellitus without 
complication 
Diabetes   0.6% 0.6% 
Other upper respiratory 
diseases 
Influenza   0.2% 
0.4%   Asthma   0.2% 
  Acute Respiratory Distress Syndrome   <0.1% 
  Allergic Rhinitis (Hay Fever)   <0.1% 
Note: The colors correspond to the classes: Class 2 is blue, 3 is orange, and 4 is yellow.  
Source: Authors’ calculation using CDC’s WONDER, Blended Account database from the BEA, and NIH’s estimates of 








This paper presents a data set that provides the medical cost, the number of patients, and 
the number of deaths per disease for 232 disease categories by identifying a set of common 
disease categories. We then sort the disease categories based on their medical expenses per 
patient, the total number of patients, total medical expenses, and mortality rates. Finally, we 
focus on the three groups that perform the worst on the four dimensions and estimate their 
NIH funding level.  
We leverage text mining and machine learning methods to facilitate merging the data and 
simplify large dimensional decision space. We find that only 25 percent of disease categories 
causing high economic and social costs received more than 1 percent of research 
investments over 12 years. In addition, rare diseases imposing high medical costs per patient 
collected 0.3 percent of research investments on average over 12 years.  
Data availability may not be the issue when assessing a disease’s economic and social 
impact, but the ability to combine the existing information and process it, is. Our analysis 
reveals that a formalized procedure to define the correspondence between data sets is 
needed to successfully develop a metric that automatizes the assessment of diseases’ cost, 
impact on society, and investment level. It also requires us to define the set of priorities that 
will guide how the data sets will be merged. In our case, we first focus on the costs 
(economic and social) to sort the diseases into four categories. Then we match the funding 
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Appendix 1: Relationship between the Measures of Cost and 
Mortality 
 
Note: Each panel plots comparisons between two variables among the four variables considered for this study (medical 
expenses per patient, the total number of patients, total medical expenses, and mortality rates). To get a better sense of what 
the classification based on the four variables entails, each data point in a class is denoted as a different color. 
 




Appendix 2: Density Functions 
 
 
Note: Each figure in four panels indicates a kernel density of data in a class according to each of four variables considered for 
this study (mortality rates, the total number of patients, medical expenses per patient, and total medical expenses). The 
horizontal axis indicates a variable range, and the vertical axis denotes probability density. To get a better sense of what the 
classification based on the four variables entails, each line for a class is denoted as a different color. 
 
Source: Authors’ calculation using CDC’s WONDER and Blended Account database from BEA (2020)
27 
 
Appendix 3: List of CCS Disease Categories per Class 
Class CCS Disease Categories 
2 
Immunizations and screening for infectious disease; Other and unspecified benign 
neoplasm; Diabetes mellitus without complication; Disorders of lipid metabolism; Other 
nervous system disorders; Essential hypertension; Nonspecific chest pain; Cardiac 
dysrhythmias; Other upper respiratory infections; Other lower respiratory disease; Other 
upper respiratory disease; Other gastrointestinal disorders; Other skin disorders; 
Osteoarthritis; Other non-traumatic joint disorders; Spondylosis, intervertebral disc 
disorders, other back problems; Other connective tissue disease; Abdominal pain; Other 
screening for suspected conditions (not mental disorders or infectious disease); Residual 
codes, unclassified; Mood disorders 
3 
Septicemia (except in labor); HIV infection; Cancer of esophagus; Cancer of stomach; Cancer 
of colon; Cancer of rectum and anus; Cancer of liver and intrahepatic bile duct; Cancer of 
pancreas; Cancer of brain and nervous system; Non-Hodgkin’s lymphoma; Leukemias; 
Multiple myeloma; Secondary malignancies; Cystic fibrosis; Sickle cell anemia; Multiple 
sclerosis; Aspiration pneumonitis, food/vomitus; Respiratory failure, insufficiency, arrest 
(adult); Appendicitis and other appendiceal conditions; Chronic kidney disease; Short 
gestation, low birth weight, and fetal growth retardation; Respiratory distress syndrome; 
Gangrene 
4 
Cancer of bronchus, lung; Acute myocardial infarction; Coronary atherosclerosis and other 
heart disease; Chronic obstructive pulmonary disease and bronchiectasis; Delirium 
dementia and amnestic and other cognitive disorders 
 
Notes: Semicolons divide each CCS disease category, and commas separate related diseases within a category.  
 






















Figure A.4.C.: Coronary 













Figure A.4.A.: Immunizations 
























































































































Figure A.4.L.: Spondylosis; 
Intervertebral Disc Disorders; 











Figure A.4.O.: Chronic Kidney 
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